These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 34552872)

  • 1. Biomarkers and Future Perspectives for Hepatocellular Carcinoma Immunotherapy.
    He Y; Lu M; Che J; Chu Q; Zhang P; Chen Y
    Front Oncol; 2021; 11():716844. PubMed ID: 34552872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma.
    Yin X; Wu T; Lan Y; Yang W
    Biosci Rep; 2022 Feb; 42(2):. PubMed ID: 35075482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations.
    Remon J; Passiglia F; Ahn MJ; Barlesi F; Forde PM; Garon EB; Gettinger S; Goldberg SB; Herbst RS; Horn L; Kubota K; Lu S; Mezquita L; Paz-Ares L; Popat S; Schalper KA; Skoulidis F; Reck M; Adjei AA; Scagliotti GV
    J Thorac Oncol; 2020 Jun; 15(6):914-947. PubMed ID: 32179179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unleashing the efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma: factors, strategies, and ongoing trials.
    Yu J; Li M; Ren B; Cheng L; Wang X; Ma Z; Yong WP; Chen X; Wang L; Goh BC
    Front Pharmacol; 2023; 14():1261575. PubMed ID: 37719852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring potential predictive biomarkers through historical perspectives on the evolution of systemic therapies into the emergence of neoadjuvant therapy for the treatment of hepatocellular carcinoma.
    Wang C; Wei F; Sun X; Qiu W; Yu Y; Sun D; Zhi Y; Li J; Fan Z; Lv G; Wang G
    Front Oncol; 2024; 14():1429919. PubMed ID: 38993637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in Immunotherapy for Hepatocellular Carcinoma.
    Hagiwara S; Nishida N; Kudo M
    Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic biomarkers associated with immune checkpoint inhibitors in hepatocellular carcinoma.
    Chen X; Kou L; Xie X; Su S; Li J; Li Y
    Immunology; 2024 May; 172(1):21-45. PubMed ID: 38214111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperprogressive disease in hepatocellular carcinoma with immune checkpoint inhibitor use: a case series.
    Wong DJ; Lee J; Choo SP; Thng CH; Hennedige T
    Immunotherapy; 2019 Feb; 11(3):167-175. PubMed ID: 30730278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer.
    Rizzo A; Ricci AD; Brandi G
    Cancers (Basel); 2021 Feb; 13(3):. PubMed ID: 33535621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Checkpoint Inhibitors as Monotherapy or Within a Combinatorial Strategy in Advanced Hepatocellular Carcinoma.
    Guardascione M; Toffoli G
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32878115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?
    Rizzo A; Ricci AD; Di Federico A; Frega G; Palloni A; Tavolari S; Brandi G
    Front Oncol; 2021; 11():803133. PubMed ID: 34976841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Checkpoint Inhibitors: A Promising Treatment Option for Metastatic Castration-Resistant Prostate Cancer?
    Ruiz de Porras V; Pardo JC; Notario L; Etxaniz O; Font A
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma.
    Machairas N; Tsilimigras DI; Pawlik TM
    Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging Opportunities for Combining Locoregional Therapy with Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
    Zeng P; Shen D; Zeng CH; Chang XF; Teng GJ
    Curr Oncol Rep; 2020 Jun; 22(8):76. PubMed ID: 32596779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Future of immune checkpoint inhibitors: focus on tumor immune microenvironment.
    Jia Y; Liu L; Shan B
    Ann Transl Med; 2020 Sep; 8(17):1095. PubMed ID: 33145314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune checkpoint inhibitors in the treatment of oesophageal squamous cell carcinoma: where are we and where are we going?
    Chen N; Xu X; Fan Y
    Ther Adv Med Oncol; 2023; 15():17588359231189420. PubMed ID: 37547447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer.
    Yang J; Chen J; Wei J; Liu X; Cho WC
    Expert Opin Biol Ther; 2016 Oct; 16(10):1209-23. PubMed ID: 27426430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential experimental immune checkpoint inhibitors for the treatment of cancer of the liver.
    Hewitt DB; Rahnemai-Azar AA; Pawlik TM
    Expert Opin Investig Drugs; 2021 Aug; 30(8):827-835. PubMed ID: 34102935
    [No Abstract]   [Full Text] [Related]  

  • 20. The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer.
    Watanabe H; Kubo T; Ninomiya K; Kudo K; Minami D; Murakami E; Ochi N; Ninomiya T; Harada D; Yasugi M; Ichihara E; Ohashi K; Fujiwara K; Hotta K; Tabata M; Maeda Y; Kiura K
    Jpn J Clin Oncol; 2019 Aug; 49(8):762-765. PubMed ID: 31090906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.